### Peter R Galle

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1578158/peter-r-galle-publications-by-year.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

511	39,792 citations	80	191
papers		h-index	g-index
597 ext. papers	48,810 ext. citations	5.4 avg, IF	7.22 L-index

#	Paper	IF	Citations
511	ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, TPS498-TPS498	2.2	2
510	Ramucirumab for patients with advanced hepatocellular carcinoma and elevated Fetoprotein following a non-sorafenib based first-line therapy: Final results from an expansion cohort of REACH-2 <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 423-423	2.2	0
509	Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer <i>JHEP Reports</i> , <b>2022</b> , 4, 100417	10.3	О
508	Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study <i>Hepatology</i> , <b>2022</b> ,	11.2	6
507	Emerging Immunotherapy for Hepatocellular Carcinoma: A Guide for Hepatologists <i>Hepatology</i> , <b>2022</b> ,	11.2	7
506	Prognostic and predictive factors in patients with advanced HCC and elevated alpha-fetoprotein treated with ramucirumab in two randomized Phase III trial Clinical Cancer Research, 2022,	12.9	2
505	Liver Frailty Index for Prediction of Short-Term Rehospitalization in Patients with Liver Cirrhosis. <i>Diagnostics</i> , <b>2022</b> , 12, 1069	3.8	
504	Influence of Advanced Organ Support (ADVOS) on Cytokine Levels in Patients with Acute-on-Chronic Liver Failure (ACLF). <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 2782	5.1	O
503	Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization <i>United European Gastroenterology Journal</i> , 2021,	5.3	2
502	Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	39
501	Association Between Serum Levels of Neurofilament Light Chains and Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , <b>2021</b> , 12, e00419	4.2	O
500	Burden of depression and anxiety disorders per disease codes in patients with lymphoma in Germany. <i>Supportive Care in Cancer</i> , <b>2021</b> , 1	3.9	
499	BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	127
498	Elevated serum levels of methylglyoxal are associated with impaired liver function in patients with liver cirrhosis. <i>Scientific Reports</i> , <b>2021</b> , 11, 20506	4.9	О
497	Immunonutritive Scoring for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
496	Reply to: "An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously". <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	1
495	Liver injury in patients with severe acute respiratory syndrome coronavirus-2 infection: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2021</b> , 33, 1194-1200	2.2	9

# (2021-2021)

494	Incident Dementia in Elderly Patients with Nonalcoholic Fatty Liver Disease in Germany. <i>Digestive Diseases and Sciences</i> , <b>2021</b> , 66, 3179-3185	4	6
493	Dr. Triantafyllias, reply. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 951	4.1	Ο
492	The Current Landscape of Clinical Trials for Systemic Treatment of HCC. Cancers, 2021, 13,	6.6	11
491	Evaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay for non-COVID-19 patient screening at hospital admission. <i>Medical Microbiology and Immunology</i> , <b>2021</b> , 210, 165-171	4	9
490	The Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy. <i>Cancers</i> , <b>2021</b> , 13,	6.6	8
489	Ramucirumab in patients with advanced hepatocellular carcinoma and elevated Efetoprotein: Outcomes by treatment-emergent ascites. <i>Hepatology Research</i> , <b>2021</b> , 51, 715-721	5.1	2
488	IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) <i>Journal of Clinical Oncology</i> , 2021, 39, 4071-4071	2.2	7
487	The impact of portal vein tumor thrombosis on survival in patients with hepatocellular carcinoma treated with different therapies: A cohort study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0249426	3.7	5
486	Health-related quality of life in patients with autoimmune hepatitis. <i>Quality of Life Research</i> , <b>2021</b> , 30, 2853-2861	3.7	О
485	Immunonutritive Scoring in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Prognostic Nutritional Index or Controlling Nutritional Status Score?. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 696183	5.3	11
484	Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. <i>Liver International</i> , <b>2021</b> , 41, 2759-2767	7.9	3
483	Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Reports, <b>2021</b> , 3, 1002	<b>60</b> 0.3	11
482	Hepatic vein tumor thrombosis in patients with hepatocellular carcinoma: Prevalence and clinical significance. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 590-597	5.3	3
481	The Addition of Transarterial Chemoembolization to Palliative Chemotherapy Extends Survival in Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	2
480	Risk factors for poorer health literacy in patients with liver cirrhosis. <i>PLoS ONE</i> , <b>2021</b> , 16, e0255349	3.7	1
479	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. <i>Hepatology</i> , <b>2021</b> , 73 Suppl 1, 158-191	11.2	63
478	Local and Regional Therapies for Hepatocellular Carcinoma. <i>Hepatology</i> , <b>2021</b> , 73 Suppl 1, 137-149	11.2	25
477	Possible misclassification of cardiovascular risk by SCORE in antisynthetase syndrome: results of the pilot multicenter study RI.CAR.D.A. <i>Rheumatology</i> , <b>2021</b> , 60, 1300-1312	3.9	Ο

476	Systemic treatment of HCC in special populations. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 931-943	13.4	22
475	Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. <i>Liver International</i> , <b>2021</b> , 41, 598-607	7.9	4
474	High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 388-397	5.3	2
473	Systemic therapy of advanced hepatocellular carcinoma. <i>Future Oncology</i> , <b>2021</b> , 17, 1237-1251	3.6	4
472	Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. <i>JHEP Reports</i> , <b>2021</b> , 3, 100215	10.3	10
471	A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, TPS349-TPS	2.2 5349	5
470	Evaluation of a novel colonoscope offering flexibility adjuster - a retrospective observational study. <i>Therapeutic Advances in Gastroenterology</i> , <b>2021</b> , 14, 17562848211013494	4.7	
469	Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC) <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 323-323	2.2	1
468	IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC) <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 267-267	2.2	107
467	Functional inhibition of Oct leads to HNF4[lipregulation. <i>Experimental and Therapeutic Medicine</i> , <b>2021</b> , 21, 349	2.1	
466	Impact of Non-Alcoholic Fatty Liver Disease on Metabolic Comorbidities in Type 2 Diabetes Mellitus. <i>Experimental and Clinical Endocrinology and Diabetes</i> , <b>2021</b> ,	2.3	2
465	No Evidence for Classic Thrombotic Microangiopathy in COVID-19. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	7
464	Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1388-1397	8.7	11
463	Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 829	5.3	1
462	Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. Journal of Thrombosis and Haemostasis, <b>2021</b> , 19, 2335-2347	15.4	6
461	Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 991-1001	21.7	37
460	Cost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis B. <i>BMC Health Services Research</i> , <b>2021</b> , 21, 846	2.9	0
459	Evaluation of novel LCI CAD EYE system for real time detection of colon polyps. <i>PLoS ONE</i> , <b>2021</b> , 16, e0255955	3.7	3

# (2020-2021)

458	Refining Prognosis in Chemoembolization for Hepatocellular Carcinoma: Immunonutrition and Liver Function. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
457	Epigenetic modifications precede molecular alterations and drive human hepatocarcinogenesis. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	2
456	NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	12
455	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma <b>2021</b> , 9,		9
454	Evaluation of atezolizumab immunogenicity: Efficacy and safety (Part 2). <i>Clinical and Translational Science</i> , <b>2021</b> ,	4.9	2
453	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 960-974	13.4	49
452	Multidisciplinary approach to the complex treatment for non-cirrhotic portal hypertension - case-report-based discussion. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2021</b> , 59, 43-49	1.6	2
45 <sup>1</sup>	Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). <i>Liver Cancer</i> , <b>2021</b> , 10, 451-460	9.1	3
450	Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	5
449	Sonographic assessment of low muscle quantity identifies mortality risk during COVID-19: a prospective single-centre study. <i>Journal of Cachexia, Sarcopenia and Muscle,</i> <b>2021</b> ,	10.3	2
448	Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. <i>Current Oncology</i> , <b>2020</b> , 27, S152-S164	2.8	7
447	Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>New England Journal of Medicine</i> , <b>2020</b> , 382, 1894-1905	59.2	1496
446	Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression. <i>Hepatology Communications</i> , <b>2020</b> , 4, 1293-1301	6	29
445	BAX Redistribution Induces Apoptosis Resistance and Selective Stress Sensitivity in Human HCC. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
444	Survival prediction for patients with non-resectable intrahepatic cholangiocarcinoma undergoing chemotherapy: a retrospective analysis comparing the tumor marker CA 19-9 with cross-sectional imaging. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 1883-1890	4.9	5
443	Patterns of liver injury in COVID-19 - a German case series. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 814-819	5.3	13
442	Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 527-536	6.1	12
441	Clinical Frailty Scale for risk stratification in patients with SARS-CoV-2 infection. <i>Journal of Investigative Medicine</i> , <b>2020</b> , 68, 1199-1202	2.9	22

440	Validation of prognostic accuracy of MESH, HKLC, and BCLC classifications in a large German cohort of hepatocellular carcinoma patients. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 444-452	5.3	5
439	In vitro prediction of in vivo absorption of ibuprofen from suspensions through rational choice of dissolution conditions. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2020</b> , 149, 229-237	5.7	10
438	Urinary ethyl glucuronide (uEtG) as a marker for alcohol consumption in liver transplant candidates: a real-world cohort. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2020</b> , 58, 30-38	1.6	2
437	A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2020</b> , 58, 57-62	1.6	3
436	Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relatives. <i>Health and Quality of Life Outcomes</i> , <b>2020</b> , 18, 10	3	3
435	Management of hepatic encephalopathy in Germany: a survey among physicians. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2020</b> , 58, 49-56	1.6	8
434	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 320-341	13.4	68
433	Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study. <i>Liver International</i> , <b>2020</b> , 40, 694-703	7.9	18
432	Risk prediction in intrahepatic cholangiocarcinoma: Direct comparison of the MEGNA score and the 8th edition of the UICC/AJCC Cancer staging system. <i>PLoS ONE</i> , <b>2020</b> , 15, e0228501	3.7	3
431	Diagnostic Value of Optical Spectral Transmission in Rheumatoid Arthritis: Associations with Clinical Characteristics and Comparison with Joint Ultrasonography. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1314-1322	4.1	5
430	Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 1754-1759	8.7	9
429	Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. <i>Liver International</i> , <b>2020</b> , 40, 2008-2020	7.9	16
428	Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC) <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 476-476	2.2	26
427	Molecular endoscopic imaging for the detection of Barrettß metaplasia using biodegradable inorganic nanoparticles: An ex-vivo pilot study on human tissue. <i>PLoS ONE</i> , <b>2020</b> , 15, e0239814	3.7	O
426	Pilot Study on Malnutrition and DNA Damage in Patients with Newly Diagnosed Gastrointestinal Tumors: Is DNA Damage Reversible by Early Individualized Nutritional Support?. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2020</b> , 29, 569-577	1.4	
425	Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease. <i>Deutsches</i> A&#x0308;rzteblatt International, <b>2020</b> , 117, 719-724	2.5	8
424	Potential Impact of IMbrave150 Results in the Evolving Treatment Landscape of Advanced Hepatocellular Carcinoma: A Multidisciplinary Expert Opinion. <i>Journal of Hepatocellular Carcinoma</i> , <b>2020</b> , 7, 423-433	5.3	1
423	Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 2112-2119	4	35

422	Sarcopenia as prognostic factor for survival after orthotopic liver transplantation. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 626-634	2.2	10
421	Symptom Burden and Treatment Response in Patients with Primary Biliary Cholangitis (PBC). <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 3006-3013	4	4
420	Treatment of cytokine storm syndrome with IL-1 receptor antagonist anakinra in a patient with ARDS caused by COVID-19 infection: A case report. <i>Clinical Case Reports (discontinued)</i> , <b>2020</b> , 8, 2990-29	9947	3
419	Impact of non-selective Eblockers on hepatic encephalopathy in patients with liver cirrhosis. <i>European Journal of Internal Medicine</i> , <b>2020</b> , 82, 83-89	3.9	1
418	Validation of the Clinical Frailty Scale for the Prediction of Mortality in Patients With Liver Cirrhosis. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00211	4.2	6
417	Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 942-948	5.3	21
416	Risk Stratification in Advanced Biliary Tract Cancer: Validation of the A.L.A.N. Score. <i>Journal of Oncology</i> , <b>2020</b> , 2020, 6180613	4.5	1
415	Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2020</b> , 52, 1042-1050	6.1	4
414	Distant Metastases in Patients with Intrahepatic Cholangiocarcinoma: Does Location Matter? A Retrospective Analysis of 370 Patients. <i>Journal of Oncology</i> , <b>2020</b> , 2020, 7195373	4.5	2
413	Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC). <i>Oncolmmunology</i> , <b>2020</b> , 9, 1806680	7.2	3
412	Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. <i>ESMO Open</i> , <b>2020</b> , 5,	6	7
411	Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
410	Proton pump inhibitor use is associated with a variety of infections in patients with liver cirrhosis. <i>Medicine (United States)</i> , <b>2020</b> , 99, e23436	1.8	4
409	Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 1141-1151	13.4	51
408	GS-09-Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology from two randomised, placebo-controlled phase 3 studies (REACH-2 and REACH). <i>Journal of Hepatology</i> , <b>2019</b> , 70, e46	13.4	6
407	Molecular endoscopic imaging: the future is bright. <i>Therapeutic Advances in Gastrointestinal Endoscopy</i> , <b>2019</b> , 12, 2631774519867175	1.6	3
406	THU-453-Dissecting the landscape of (epi-)genetic alterations during sequential evolution of liver cancer. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e358-e359	13.4	4
405	Health-related quality of life in patients with compensated and decompensated liver cirrhosis. European Journal of Internal Medicine, <b>2019</b> , 70, 54-59	3.9	18

404	A novel technique for intraduodenal administration of drug suspensions/solutions with concurrent pH monitoring applied to ibuprofen formulations. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2019</b> , 136, 192-202	5.7	7
403	Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased Efetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 282-296	21.7	704
402	Loss of Expression Correlates with Diffuse Gastric Cancer and Distant Peritoneal Metastases. <i>Canadian Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 2019, 2920493	2.8	2
401	The role of sarcopenia in patients with intrahepatic cholangiocarcinoma: Prognostic marker or hyped parameter?. <i>Liver International</i> , <b>2019</b> , 39, 1307-1314	7.9	14
400	Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy. <i>Journal of Clinical Gastroenterology</i> , <b>2019</b> , 53, e303-e307	3	11
399	Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters - an animal model of life style intervention in NAFLD. <i>Scientific Reports</i> , <b>2019</b> , 9, 4007	4.9	17
398	Expression and prognostic significance of insulin-like growth factor-2 receptor in human hepatocellular carcinoma and the influence of transarterial chemoembolization. <i>Oncology Reports</i> , <b>2019</b> , 41, 2299-2310	3.5	3
397	Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 529-537	5.3	10
396	Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of Efetoprotein. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, e191	21.7	27
395	Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2085-2092.e1	6.9	41
394	Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. <i>Liver International</i> , <b>2019</b> , 39, 2214-2229	7.9	116
393	Deletion of organic cation transporter Oct3 promotes hepatic fibrosis via upregulation of TGFI <i>American Journal of Physiology - Renal Physiology</i> , <b>2019</b> , 317, G195-G202	5.1	7
392	Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 838-849	5.3	10
391	Improvement of non-invasive markers of NAFLD from an individualised, web-based exercise program. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 930-939	6.1	36
390	Comparison of the current international guidelines on the management of HCC. <i>JHEP Reports</i> , <b>2019</b> , 1, 114-119	10.3	15
389	Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low-Density Lipoprotein Cholesterol. <i>Hepatology Communications</i> , <b>2019</b> , 3, 1472-1481	6	18
388	Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 50, 1112-1119	6.1	8
387	Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2) <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4073-4073	2.2	6

### (2018-2019)

386	A phase II, open label, multicenter trial of avelumab in patients with advanced, metastatic high-grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after first-line chemotherapy (AVENEC) <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4103-4103	2.2	20
385	Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, TPS4152-TPS4152	2.2	62
384	Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline Efetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 326-326	2.2	5
383	Cirrhosis risk score of the donor organ predicts early fibrosis progression after liver transplantation. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2019</b> , 28, 53-61	1.4	2
382	Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 764-770	0.7	21
381	Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases. <i>Annals of Surgery</i> , <b>2019</b> , 270, 799-805	7.8	36
380	Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy. <i>European Journal of Internal Medicine</i> , <b>2019</b> , 60, 96-100	3.9	12
379	Improved Prediction of Survival by a Risk Factor-Integrating Inflammatory Score in Sorafenib-Treated Hepatocellular Carcinoma. <i>Liver Cancer</i> , <b>2019</b> , 8, 387-402	9.1	10
378	Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program. <i>BMC Cancer</i> , <b>2019</b> , 19, 55	4.8	17
377	Alternative Splice Forms of CYLD Mediate Ubiquitination of SMAD7 to Prevent TGFB Signaling and Promote Colitis. <i>Gastroenterology</i> , <b>2019</b> , 156, 692-707.e7	13.3	15
376	Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse?. <i>Liver International</i> , <b>2019</b> , 39, 324-331	7.9	28
375	Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 2782-2794	7.5	12
374	High cardiovascular risk in mixed connective tissue disease: evaluation of macrovascular involvement and its predictors by aortic pulse wave velocity. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 994-1002	2.2	2
373	Patient prioritisation in HCC treatment: All (good) things come in threes. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 1311-1312	13.4	O
372	The role of molecular enrichment on future therapies in hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 237-247	13.4	65
371	EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 182-236	13.4	3196
370	Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 986-995	13.4	62
369	The Manchester Triage System (MTS): a score for emergency management of patients with acute gastrointestinal bleeding. Zeitschrift Fur Gastroenterologie, 2018, 56,	1.6	2

368	Advanced endoscopic imaging for diagnosis of inflammatory bowel diseases: Present and future perspectives. <i>Digestive Endoscopy</i> , <b>2018</b> , 30, 441-448	3.7	7
367	Prediction of clinical outcomes in Crohnß disease by using confocal laser endomicroscopy: results from a prospective multicenter study. <i>Gastrointestinal Endoscopy</i> , <b>2018</b> , 87, 1505-1514.e3	5.2	18
366	Hepatocellular carcinoma in 2017: Two large steps forward, one small step back. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2018</b> , 15, 74-76	24.2	15
365	The immune contexture of hepatocellular carcinoma predicts clinical outcome. <i>Scientific Reports</i> , <b>2018</b> , 8, 5351	4.9	62
364	Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. <i>Digestive Diseases</i> , <b>2018</b> , 36, 78-88	3.2	4
363	Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort. <i>BMC Cancer</i> , <b>2018</b> , 18, 774	4.8	7
362	Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma. <i>BMC Cancer</i> , <b>2018</b> , 18, 489	4.8	10
361	Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 982-984	13.4	17
360	Interferon- and ribavirin-free therapy with new direct acting antivirals (DAA) for chronic hepatitis C improves vascular endothelial function. <i>International Journal of Cardiology</i> , <b>2018</b> , 271, 296-300	3.2	19
359	Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation-a prospective single-center cohort study. <i>Transplant International</i> , <b>2018</b> , 31, 1207-1215	3	19
358	Recipient liver function before liver transplantation influences post-transplantation survival in patients with HCC. <i>European Journal of Internal Medicine</i> , <b>2018</b> , 55, 57-65	3.9	5
357	REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib <i>Journal of Clinical</i>	2.2	62
356	IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS414	1-7PS	<b>1</b> ₹41
355	A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS4144-TPS4144	2.2	55
354	A study of ramucirumab (LY3009806) versus placebo in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein (REACH-2) <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS538-TPS538	2.2	19
353	Loss of cellular FLICE-inhibitory protein promotes acute cholestatic liver injury and inflammation from bile duct ligation. <i>American Journal of Physiology - Renal Physiology</i> , <b>2018</b> , 314, G319-G333	5.1	10
352	Ginkgo biloba induces different gene expression signatures and oncogenic pathways in malignant and non-malignant cells of the liver. <i>PLoS ONE</i> , <b>2018</b> , 13, e0209067	3.7	9
351	Hepatitis E virus genotype 3 is a common finding in liver-transplanted patients undergoing liver biopsy for elevated liver enzymes with a low De Ritis ratio and suspected acute rejection: A real-world cohort. <i>Clinical Transplantation</i> , <b>2018</b> , 32, e13411	3.8	5

350	Helicobacter pylori Infection as a Risk Factor for Hepatocellular Carcinoma: A Case-Control Study in Ethiopia. <i>International Journal of Hepatology</i> , <b>2018</b> , 2018, 1941728	2.7	5
349	Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.  Alimentary Pharmacology and Therapeutics, 2018, 48, 1109-1116	6.1	53
348	Leaving colorectal polyps in place can be achieved with high accuracy using blue light imaging (BLI). <i>United European Gastroenterology Journal</i> , <b>2018</b> , 6, 1099-1105	5.3	12
347	Feasibility Trial of the Newly Introduced Optical Enhancement Technology in Patients with Gastroesophageal Reflux Disease. <i>Digestive Diseases</i> , <b>2018</b> , 36, 450-455	3.2	
346	Molecular endoscopic imaging in cancer. <i>Digestive Endoscopy</i> , <b>2018</b> , 30, 719-729	3.7	9
345	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 68, 16-24	14.4	89
344	Activation of silent mating type information regulation 2 homolog 1 by human chorionic gonadotropin exerts a therapeutic effect on hepatic injury and inflammation. <i>Hepatology</i> , <b>2017</b> , 65, 20	74 <del>-2</del> 68	93
343	Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , <b>2017</b> , 40, 1017-1025	2.7	14
342	Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2017</b> , 143, 1023-103	34 <sup>4.9</sup>	2
341	Immune oncology in hepatocellular carcinoma-hype and hope. <i>Lancet, The</i> , <b>2017</b> , 389, 2448-2449	40	7
340	Elevated levels of Bcl-3 inhibits Treg development and function resulting in spontaneous colitis. <i>Nature Communications</i> , <b>2017</b> , 8, 15069	17.4	13
339	Treating Hepatobiliary Cancers: The Oncology Way. <i>Digestive Diseases</i> , <b>2017</b> , 35, 384-386	3.2	5
338	Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , <b>2017</b> , 5, 987-996	5.3	33
337	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 173-183	13.4	106
336	Reply to: "Performance status in patients with HCC: New kid on the block". <i>Journal of Hepatology</i> , <b>2017</b> , 67, 1353-1355	13.4	1
335	Voluntary distance running prevents TNF-mediated liver injury in mice through alterations of the intrahepatic immune milieu. <i>Cell Death and Disease</i> , <b>2017</b> , 8, e2893	9.8	10
334	Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5720-5728	12.9	47
333	Validation of Clinical Scoring Systems ART and ABCR after Transarterial Chemoembolization of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , <b>2017</b> , 28, 94-102	2.4	23

332	Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver transplantation: a real-world cohort. <i>Drug Design, Development and Therapy,</i> <b>2017</b> , 11, 2131-2138	4.4	9
331	Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , <b>2017</b> , 114, 597-602	2.5	7
330	A phase 2 study of galunisertib (TGF-IR1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC) <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 4097-4097	2.2	5
329	Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-B activation. <i>Oncotarget</i> , <b>2017</b> , 8, 56095-56109	3.3	7
328	Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas. <i>Oncotarget</i> , <b>2017</b> , 8, 48688-48700	3.3	12
327	Loss of organic cation transporter 3 (Oct3) leads to enhanced proliferation and hepatocarcinogenesis. <i>Oncotarget</i> , <b>2017</b> , 8, 115667-115680	3.3	12
326	Portal vein infiltration in patients with hepatocellular carcinoma: The relevance of correct classification <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e15651-e15651	2.2	
325	Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2016</b> , 28, 187-9	2 <sup>2.2</sup>	2
324	Surveillance of Hepatocellular Carcinoma and Diagnostic Algorithms in Patients with Liver Cirrhosis. <i>Visceral Medicine</i> , <b>2016</b> , 32, 110-5	2.4	9
323	Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 1188-1197	13.4	10
322	Analysis of the expression of SDF-1 splicing variants in human colorectal cancer and normal mucosa tissues. <i>Oncology Letters</i> , <b>2016</b> , 11, 1873-1878	2.6	8
321	Functional diversity of stromal cell-derived factor 1 splice variants in colorectal cancer and melanoma. <i>International Journal of Colorectal Disease</i> , <b>2016</b> , 31, 1225-6	3	
320	Changes in lipid and carbohydrate metabolism under mTOR- and calcineurin-based immunosuppressive regimen in adult patients after liver transplantation. <i>European Journal of Internal Medicine</i> , <b>2016</b> , 29, 104-9	3.9	16
319	Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. <i>BMC Cancer</i> , <b>2016</b> , 16, 94	4.8	32
318	The 9th Annual Conference of the International Liver Cancer Association (ILCA) 2015. <i>Hepatic Oncology</i> , <b>2016</b> , 3, 9-12	4	
317	Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 291-7	3.3	31
316	PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS4146-TPS4146	2.2	28
315	A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2) Journal of Clinical Oncology, 2016, 34, TPS4	2.2 78-TPS	2 478

314	The Impact of Liver Cell Injury on Health-Related Quality of Life in Patients with Chronic Liver Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0151200	3.7	16
313	Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Nawe Patients Infected with Hepatitis C Virus Genotype 1. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2016</b> , 25, 15-24	1.4	3
312	Cholelithiasis in Patients with Gaucher Disease type 1: Risk Factors and the Role of ABCG5/ABCG8 Gene Variants. <i>Journal of Gastrointestinal and Liver Diseases</i> , <b>2016</b> , 25, 447-455	1.4	6
311	Increased liver carcinogenesis and enrichment of stem cell properties in livers of Dickkopf 2 (Dkk2) deleted mice. <i>Oncotarget</i> , <b>2016</b> , 7, 28903-13	3.3	5
310	A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2) <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, TPS4	2.2 145-TP	2 PS4145
309	Dermatux: Phase IV trial of C-FOLFIRI in 1st-line metastatic colorectal cancer receiving a pre-defined skin care <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e15048-e15048	2.2	
308	Validation of clinical scoring systems ART and ABCR after transarterial chemoembolization of hepatocellular carcinoma <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e15593-e15593	2.2	
307	Last line therapy with sorafenib in colorectal cancer: A retrospective analysis. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 5400-5	5.6	6
306	Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. <i>BMC Cancer</i> , <b>2016</b> , 16, 699	4.8	37
305	Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients. <i>Clinical Gastroenterology and Hepatology</i> , <b>2016</b> , 14, 875-886.e6	6.9	141
304	Extended Abstract: Management of Liver Cancer. <i>Digestive Diseases</i> , <b>2016</b> , 34, 438-9	3.2	6
303	Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. <i>CardioVascular and Interventional Radiology</i> , <b>2015</b> , 38, 352-60	2.7	63
302	Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 863-70	13.4	45
301	Curcumin effectively inhibits oncogenic NF- <b>B</b> signaling and restrains stemness features in liver cancer. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 661-9	13.4	182
300	Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort. <i>BMC Gastroenterology</i> , <b>2015</b> , 15, 97	3	18
299	Translating bioinformatics in oncology: guilt-by-profiling analysis and identification of KIF18B and CDCA3 as novel driver genes in carcinogenesis. <i>Bioinformatics</i> , <b>2015</b> , 31, 216-24	7.2	47
298	Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation. <i>Liver International</i> , <b>2015</b> , 35, 176-83	7.9	3
297	Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients. Journal of Clinical Gastroenterology, <b>2015</b> , 49, 438-47	3	10

296	Efficacy and safety of a conversion from the original tacrolimus and mycophenolate mofetil to the generics Tacpan and Mowel after liver transplantation. <i>Drug Design, Development and Therapy</i> , <b>2015</b> , 9, 6139-49	4.4	3
295	Treatment and survival of non-alcoholic steatohepatitis associated hepatocellular carcinoma. <i>BMC Cancer</i> , <b>2015</b> , 15, 210	4.8	62
294	Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. <i>Liver International</i> , <b>2015</b> , 35, 591-600	7.9	50
293	Familial amyloidosis: great progress for an orphan disease. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 483-5	13.4	4
292	Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2015</b> , 141, 515-22	4.9	9
291	Intraprocedural bowel cleansing with the JetPrep cleansing system improves adenoma detection. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 8184-94	5.6	8
<b>29</b> 0	Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 88-9	3.3	13
289	Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1268-89	13.4	815
288	Erythropoietin treatment in chemotherapy-induced anemia in previously untreated advanced esophagogastric cancer patients. <i>International Journal of Clinical Oncology</i> , <b>2014</b> , 19, 288-96	4.2	9
287	Sequential transcriptome analysis of human liver cancer indicates late stage acquisition of malignant traits. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 346-353	13.4	63
286	Treatment of malignant ascites with a second cycle of catumaxomab in gastric signet cell carcinomaa report of 2 cases. <i>Oncology Research and Treatment</i> , <b>2014</b> , 37, 674-7	2.8	5
285	HCC therapieslessons learned. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2014</b> , 11, 447-52	24.2	113
284	High definition plus colonoscopy combined with i-scan tone enhancement vs. high definition colonoscopy for colorectal neoplasia: A randomized trial. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 991-6	3.3	21
283	High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. <i>International Journal of Cancer</i> , <b>2014</b> , 134, 1926-34	7.5	70
282	VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). <i>BMC Cancer</i> , <b>2014</b> , 14, 476	4.8	8
281	Selective internal radiotherapy (SIRT) versus transarterial chemoembolization (TACE) for the treatment of intrahepatic cholangiocellular carcinoma (CCC): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2014</b> , 15, 311	2.8	18
280	Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia. <i>Nature Genetics</i> , <b>2014</b> , 46, 901-4	36.3	75
279	Acetic acid compared with i-scan imaging for detecting Barrettß esophagus: a randomized, comparative trial. <i>Gastrointestinal Endoscopy</i> , <b>2014</b> , 79, 46-54	5.2	34

278	Impact of pancreatic comorbidities in patients with end-stage liver disease on outcome after liver transplantation. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 281-5	3.9	8
277	Analysis of interobserver variability for endomicroscopy of the gastrointestinal tract. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 140-5	3.3	7
276	Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents. <i>Digestive and Liver Disease</i> , <b>2014</b> , 46, 67-71	3.3	7
275	Triple antiviral therapy with telaprevir after liver transplantation: a case series. <i>Transplant Research and Risk Management</i> , <b>2014</b> , 73	1.1	2
274	Disclosure and Experienced Social Support are not Related to Anxiety or Depression in a German HIV Patient Cohort. <i>Infection and Chemotherapy</i> , <b>2014</b> , 46, 77-83	3.9	7
273	Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2014</b> , 33, 83	12.8	12
272	Moguntinonesnew selective inhibitors for the treatment of human colorectal cancer. <i>Molecular Cancer Therapeutics</i> , <b>2014</b> , 13, 1399-409	6.1	4
271	Immune control in hepatocellular carcinoma development and progression: role of stromal cells. <i>Seminars in Liver Disease</i> , <b>2014</b> , 34, 376-88	7.3	26
270	Sorafenib for the treatment of hepatocellular carcinoma. <i>Hepatic Oncology</i> , <b>2014</b> , 1, 189-204	4	5
269	Overexpression of Bcl-3 inhibits the development of marginal zone B cells. <i>European Journal of Immunology</i> , <b>2014</b> , 44, 545-52	6.1	14
268	CellMinerHCC: a microarray-based expression database for hepatocellular carcinoma cell lines. <i>Liver International</i> , <b>2014</b> , 34, 621-31	7.9	12
267	Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry. <i>Journal of Clinical Gastroenterology</i> , <b>2014</b> , 48, 279-89	3	64
266	Confocal endomicroscopy identifies loss of local barrier function in the duodenum of patients with Crohnß disease and ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , <b>2014</b> , 20, 892-900	4.5	53
265	Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 92	5.3	20
264	To biopsy or not to biopsy: evaluation of a large German cohort of patients with abnormal liver tests of unknown etiology. <i>Digestion</i> , <b>2014</b> , 89, 310-8	3.6	2
263	Efficacy of SpyGlass(TM)-directed biopsy compared to brush cytology in obtaining adequate tissue for diagnosis in patients with biliary strictures. <i>World Journal of Gastrointestinal Endoscopy</i> , <b>2014</b> , 6, 137	7- <del>43</del>	23
262	A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and skin prophylaxis aiming to prevent a skin rash <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e20724-e20724	2.2	
261	A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, TPS3658-TPS3658	2.2	

260	Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction. <i>BMC Cancer</i> , <b>2013</b> , 13, 75	4.8	7
259	PR3 antibodies do not induce renal pathology in a novel PR3-humanized mouse model for Wegenerß granulomatosis. <i>Rheumatology International</i> , <b>2013</b> , 33, 613-22	3.6	6
258	Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograftno benefit of combination therapy. <i>International Journal of Colorectal Disease</i> , <b>2013</b> , 28, 385	-98	15
257	Familial amyloid polyneuropathy. <i>Digestive Diseases</i> , <b>2013</b> , 31, 170-4	3.2	15
256	Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1. <i>International Journal of Cancer</i> , <b>2013</b> , 132, 2548-56	7.5	29
255	Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. Journal of Cancer Research and Clinical Oncology, 2013, 139, 1667-72	4.9	16
254	Sirtuin-6-dependent genetic and epigenetic alterations are associated with poor clinical outcome in hepatocellular carcinoma patients. <i>Hepatology</i> , <b>2013</b> , 58, 1054-64	11.2	113
253	Next generation sequencing of HCC from European and Asian HCC cohorts. Back to p53 and Wnt/Eatenin. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 622-4	13.4	10
252	The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 408-13	3.3	28
251	No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trial. <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 323	<b>_</b> 3.3	5
250	Metabolic syndrome and its association with fatty liver disease after orthotopic liver transplantation. <i>Transplant International</i> , <b>2013</b> , 26, 67-74	3	48
249	Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. <i>International Journal of Oncology</i> , <b>2013</b> , 42, 1297-304	4.4	35
248	Late consequences of traumatic rupture of the diaphragm. <i>Thoracic and Cardiovascular Surgeon</i> , <b>2013</b> , 61, 267-9	1.6	1
247	Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2013</b> , 25, 639-51	2.2	27
246	Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells. <i>Hepatology</i> , <b>2013</b> , 57, 2358-68	11.2	108
245	Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer cells. <i>OncoTargets and Therapy</i> , <b>2013</b> , 6, 1119-27	4.4	14
244	CellLineNavigator: a workbench for cancer cell line analysis. <i>Nucleic Acids Research</i> , <b>2013</b> , 41, D942-8	20.1	14
243	Education in organ donation among students in Germany - results of an intervention study. <i>Annals of Transplantation</i> , <b>2013</b> , 18, 23-30	1.4	7

### (2012-2013)

242	Irritable bowel syndrome and organic diseases: a comparative analysis of esophageal motility. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 6408-15	5.6	2
241	Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. <i>BMC Cancer</i> , <b>2012</b> , 12, 109	4.8	77
240	Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously. <i>Oncology Letters</i> , <b>2012</b> , 3, 1191-1194	2.6	5
239	Identification of RARRES1 as a core regulator in liver fibrosis. <i>Journal of Molecular Medicine</i> , <b>2012</b> , 90, 1439-47	5.5	8
238	18F-Fluorodeoxyglucose positron-emission tomography (PET) can be used to assess inflammation non-invasively in Crohnß disease. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 2658-68	4	30
237	Novel insights in the genetics of HCC recurrence and advances in transcriptomic data integration. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 279-81	13.4	17
236	Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 267-75	13.4	133
235	Snapshot liver transcriptome in hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 990-2	13.4	11
234	Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 821-9	13.4	589
233	Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. <i>Journal of Clinical Virology</i> , <b>2012</b> , 54, 93-5	14.5	44
232	RNA-Seq Atlasa reference database for gene expression profiling in normal tissue by next-generation sequencing. <i>Bioinformatics</i> , <b>2012</b> , 28, 1184-5	7.2	139
231	LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial. <i>BMC Cancer</i> , <b>2012</b> , 12, 144	4.8	13
230	Genetic signatures shared in embryonic liver development and liver cancer define prognostically relevant subgroups in HCC. <i>Molecular Cancer</i> , <b>2012</b> , 11, 55	42.1	29
229	Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. <i>Gastroenterology</i> , <b>2012</b> , 142, 782-789.e3	13.3	270
228	Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. <i>Digestive and Liver Disease</i> , <b>2012</b> , 44, 432-7	3.3	47
227	Molecular in vivo imaging of gastric cancer in a human-murine xenograft model: targeting epidermal growth factor receptor. <i>Gastrointestinal Endoscopy</i> , <b>2012</b> , 76, 612-20	5.2	35
226	Liver-specific overexpression of matrix metalloproteinase 9 (MMP-9) in transgenic mice accelerates development of hepatocellular carcinoma. <i>Molecular Carcinogenesis</i> , <b>2012</b> , 51, 439-48	5	19
225	Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 69, 1601-15	3.5	61

224	The role of death effector domain-containing proteins in acute oxidative cell injury in hepatocytes. <i>Free Radical Biology and Medicine</i> , <b>2012</b> , 52, 1911-7	7.8	14
223	Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. <i>Seminars in Liver Disease</i> , <b>2012</b> , 32, 348-59	7.3	387
222	Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocyte-specific deletion of cFLIP. <i>American Journal of Physiology - Renal Physiology</i> , <b>2012</b> , 303, G498-506	5.1	22
221	Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. <i>Scandinavian Journal of Gastroenterology</i> , <b>2012</b> , 47, 718-28	2.4	30
220	Clinicopathologic features and prognosis of young patients with hepatocellular carcinoma in a large German cohort. <i>Journal of Clinical Gastroenterology</i> , <b>2012</b> , 46, 775-8	3	13
219	Selective PI3K inhibition by BKM120 and BEZ235 lalone or in combination with the mother apy in wild-type and mutated human gastrointestinal cancer cell lines <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 522-522	2.2	2
218	Preservation of HUGL-1 expression as a favourable prognostic factor in pancreatic carcinoma. <i>Anticancer Research</i> , <b>2012</b> , 32, 3153-9	2.3	8
217	New imaging techniques and opportunities in endoscopy. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2011</b> , 8, 547-53	24.2	46
216	Alterations in lipid, carbohydrate and iron metabolism in patients with non-alcoholic steatohepatitis (NASH) and metabolic syndrome. <i>European Journal of Internal Medicine</i> , <b>2011</b> , 22, 305-1	10 <sup>3.9</sup>	25
215	Ablation of c-FLIP in hepatocytes enhances death-receptor mediated apoptosis and toxic liver injury in vivo. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 1272-80	13.4	50
214	In vivo real-time imaging of the liver with confocal endomicroscopy permits visualization of the temporospatial patterns of hepatocyte apoptosis. <i>American Journal of Physiology - Renal Physiology</i> , <b>2011</b> , 301, G764-72	5.1	18
213	Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2011</b> , 26 Suppl 1, 213-9	4	85
212	The recipient CYP2D6 allele 4-associated poor metabolizer status correlates with an early fibrosis development after liver transplantation. <i>Transplant International</i> , <b>2011</b> , 24, 1059-67	3	2
211	Expression of chemokine receptor CCR5 correlates with the presence of hepatic molecular metastases in K-ras positive human colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2011</b> , 137, 1139-45	4.9	7
210	Comparative aspects of murine proteinase 3. Rheumatology International, 2011, 31, 1105-11	3.6	7
209	VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery. <i>World Journal of Surgery</i> , <b>2011</b> , 35, 1010-6	3.3	13
208	Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. <i>BMC Cancer</i> , <b>2011</b> , 11, 464	4.8	27
207	The functional cancer map: a systems-level synopsis of genetic deregulation in cancer. <i>BMC Medical Genomics</i> , <b>2011</b> , 4, 53	3.7	29

206	IRF4 regulates IL-17A promoter activity and controls RORE-dependent Th17 colitis in vivo. <i>Inflammatory Bowel Diseases</i> , <b>2011</b> , 17, 1343-58	4.5	66
205	Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. <i>International Journal of Cancer</i> , <b>2011</b> , 128, 125	9 <sup>7</sup> 68	51
204	Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. <i>Gut</i> , <b>2011</b> , 60, 26-33	19.2	85
203	Pregnancy in primary sclerosing cholangitis. <i>Gut</i> , <b>2011</b> , 60, 1117-21	19.2	47
202	SNP rs1801157 significantly correlates with distant metastasis in CXCL12 expressing esophagogastric cancer. <i>International Journal of Oncology</i> , <b>2011</b> , 39, 515-20	4.4	6
201	AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature. <i>Onkologie</i> , <b>2011</b> , 34, 538-42		4
200	New perspectives on the renal slit diaphragm protein podocin. <i>Modern Pathology</i> , <b>2011</b> , 24, 1101-10	9.8	17
199	Mini-laparoscopy in the endoscopy unit: Safety and outcomes in over one thousand patients. <i>World Journal of Gastrointestinal Endoscopy</i> , <b>2011</b> , 3, 6-10	2.2	9
198	Collecting evidence for a stem cell hypothesis in HCC. <i>Gut</i> , <b>2010</b> , 59, 870-1	19.2	10
197	Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 60-70	4.1	114
196	Molecular imaging of VEGF in gastrointestinal cancer in vivo using confocal laser endomicroscopy. <i>Gut</i> , <b>2010</b> , 59, 1046-55	19.2	100
195	Np73IIs oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. <i>Cell Cycle</i> , <b>2010</b> , 9, 2629-39	4.7	24
194	Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. <i>Oncology</i> , <b>2010</b> , 79, 85-92	3.6	33
193	Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study. <i>Onkologie</i> , <b>2010</b> , 33, 684-90		3
192	Future perspectives in hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42 Suppl 3, S302-9	3.3	55
191	In vivo molecular imaging of colorectal cancer with confocal endomicroscopy by targeting epidermal growth factor receptor. <i>Gastroenterology</i> , <b>2010</b> , 138, 435-46	13.3	176
190	Near-infrared confocal imaging during mini-laparoscopy: a novel rigid endomicroscope with increased imaging plane depth. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 84-90	13.4	55
189	Liver-specific Ldb1 deletion results in enhanced liver cancer development. <i>Journal of Hepatology</i> , <b>2010</b> , 53, 1078-84	13.4	14

188	Liver transplanted patients with preoperative autoimmune hepatitis and immunological disorders are at increased risk for Post-Transplant Lymphoproliferative Disease (PTLD). <i>European Journal of Internal Medicine</i> , <b>2010</b> , 21, 208-15	3.9	17
187	Novel inhibitors in development for hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , <b>2010</b> , 19, 615-29	5.9	24
186	Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. <i>International Journal of Cancer</i> , <b>2010</b> , 127, 1197-208	7.5	24
185	Microarray-based gene expression analysis of hepatocellular carcinoma. <i>Current Genomics</i> , <b>2010</b> , 11, 261-8	2.6	26
184	Concurrent autoimmune diseases in patients with autoimmune hepatitis. <i>Journal of Clinical Gastroenterology</i> , <b>2010</b> , 44, 208-13	3	138
183	Cetuximab-induced skin exanthema: Improvement by a reactive skin therapy. <i>Molecular Medicine Reports</i> , <b>2010</b> , 3, 789-93	2.9	2
182	A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro-oesophageal junction: a study of the Arbeitsgemeinschaft Internistische Onkologie. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2010</b> , 66, 191-5	3·5 5	8
181	K-ras mutation status correlates with the expression of VEGFR1, VEGFR2, and PDGFRalpha in colorectal cancer. <i>International Journal of Colorectal Disease</i> , <b>2010</b> , 25, 181-6	3	18
180	Low expression of chemokine receptor CCR5 in human colorectal cancer correlates with lymphatic dissemination and reduced CD8+ T-cell infiltration. <i>International Journal of Colorectal Disease</i> , <b>2010</b> , 25, 417-24	3	25
179	Significant differences between CrohnB disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 1066-78	4	30
178	Library of molecular associations: curating the complex molecular basis of liver diseases. <i>BMC Genomics</i> , <b>2010</b> , 11, 189	4.5	11
177	Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. <i>Hepatology</i> , <b>2010</b> , 51, 1226-36	11.2	88
176	Perforin deficiency attenuates inflammation and tumor growth in colitis-associated cancer. <i>Inflammatory Bowel Diseases</i> , <b>2010</b> , 16, 559-67	4.5	12
175	Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation. <i>Liver Transplantation</i> , <b>2010</b> , 16, 109	4.5	34
174	Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. <i>Liver Transplantation</i> , <b>2010</b> , 16, 314-23	4.5	55
173	Contrast-enhanced ultrasonography with SonoVue: differentiation between benign and malignant lesions of the spleen. <i>Journal of Ultrasound in Medicine</i> , <b>2009</b> , 28, 421-34	2.9	37
172	High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 2089-96	5.6	174
171	IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. <i>Cancer Research</i> , <b>2009</b> , 69, 855-62	10.1	58

170	Systemic therapies in hepatocellular carcinoma. <i>Digestive Diseases</i> , <b>2009</b> , 27, 175-88	3.2	50
169	Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy. <i>Kidney International</i> , <b>2009</b> , 75, 399-407	9.9	20
168	Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. <i>Hepatology</i> , <b>2009</b> , 49, 627-36	11.2	111
167	EGF and HGF levels are increased during active HBV infection and enhance survival signaling through extracellular matrix interactions in primary human hepatocytes. <i>International Journal of Cancer</i> , <b>2009</b> , 124, 120-9	7.5	21
166	Immunoadsorption with tryptophan columns: a therapeutic option for the treatment of rheumatoid arthritis with septic complications. <i>Journal of Clinical Apheresis</i> , <b>2009</b> , 24, 37-41	3.2	1
165	IRF4 selectively controls cytokine gene expression in chronic intestinal inflammation. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , <b>2009</b> , 57, 369-76	4	8
164	A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 1122-31	13.4	16
163	Show me your signalingand IRI tell you who you are. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 638-9	13.4	2
162	Coexistence of Cullenß and Grey Turnerß signs in acute pancreatitis. <i>American Journal of Medicine</i> , <b>2009</b> , 122, 333-4	2.4	15
161	Confocal Laser Endomicroscopy for the In Vivo Identification, Localization and Quantification of Tissue Based Bacteria in Patients with Different Types of Colitis. <i>Gastrointestinal Endoscopy</i> , <b>2009</b> , 69, AB131	5.2	4
160	High Definition Plus Colonoscopy Combined with I-Scan Is Superior in the Detection and Characterization of Colorectal Neoplasias Compared to Standard Video Colonoscopy - A Prospective Randomized Trial. <i>Gastrointestinal Endoscopy</i> , <b>2009</b> , 69, AB131-AB132	5.2	4
159	Simultaneous confocal laser endomicroscopy and chromoendoscopy with topical cresyl violet. <i>Gastrointestinal Endoscopy</i> , <b>2009</b> , 70, 959-68	5.2	72
158	Small Bowel Enteroscopy: Feasibility and Safety of the New Balloon Guided Endoscopy System Using Different High Definition, Confocal and Standard Endoscopes. <i>Gastrointestinal Endoscopy</i> , <b>2009</b> , 69, AB364	5.2	2
157	Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. <i>Journal of Clinical Gastroenterology</i> , <b>2009</b> , 43, 75-80	3	63
156	Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. <i>Journal of Clinical Gastroenterology</i> , <b>2009</b> , 43, 489-	· <i>9</i> 5	125
155	Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 449-56	5.6	29
154	Hepatocellular carcinoma in patients with autoimmune hepatitis. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 578-82	5.6	53
153	TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 5924-35	5.6	31

152	All-trans retinoic acid for treatment of chronic hepatitis C. Liver International, 2008, 28, 347-54	7.9	22
151	Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 2008, 359, 378-90	59.2	9089
150	Staging of Colorectal Neoplasia with Confocal Laser Endomicroscopy Using Two Contrast Agents Simultaneously. <i>Gastrointestinal Endoscopy</i> , <b>2008</b> , 67, AB123	5.2	4
149	High Definition Colonoscopy (HD+) with I-Scan Function Allows to Recognize and Characterize Flat Neoplastic Changes As Precisely As Chromoendoscopy. <i>Gastrointestinal Endoscopy</i> , <b>2008</b> , 67, AB125	5.2	7
148	Mycophenolate mofetil as second line therapy in autoimmune hepatitis?. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 3063-70	0.7	145
147	In vivo confocal laser laparoscopy allows real time subsurface microscopy in animal models of liver disease. <i>Journal of Hepatology</i> , <b>2008</b> , 48, 91-7	13.4	27
146	Sorafenib in advanced hepatocellular carcinoma - We have won a battle not the war. <i>Journal of Hepatology</i> , <b>2008</b> , 49, 871-3	13.4	24
145	Human leukocyte elastase counteracts matrix metalloproteinase-7 induced apoptosis resistance of tumor cells. <i>Cancer Letters</i> , <b>2008</b> , 268, 331-9	9.9	5
144	Cloning and characterization of the promoter of Hugl-2, the human homologue of Drosophila lethal giant larvae (lgl) polarity gene. <i>Biochemical and Biophysical Research Communications</i> , <b>2008</b> , 366, 1067-7	<b>13</b> ·4	12
143	Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. <i>Gene</i> , <b>2008</b> , 423, 23-8	3.8	45
142	The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. <i>Journal of Experimental Medicine</i> , <b>2008</b> , 205, 2099-110	16.6	85
141	Cutting edge: a key pathogenic role of IL-27 in T cell- mediated hepatitis. <i>Journal of Immunology</i> , <b>2008</b> , 180, 30-3	5.3	38
140	Transforming growth factor-beta-mediated tumor necrosis factor-related apoptosis-inducing ligand expression and apoptosis in hepatoma cells requires functional cooperation between Smad proteins and activator protein-1. <i>Molecular Cancer Research</i> , <b>2008</b> , 6, 1169-77	6.6	18
139	Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 138-46	0.7	39
138	Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. <i>Journal of Clinical Gastroenterology</i> , <b>2008</b> , 42, 926-30	3	96
137	Strong expression of chemokine receptor CXCR4 by renal cell carcinoma correlates with advanced disease. <i>Journal of Oncology</i> , <b>2008</b> , 2008, 626340	4.5	24
136	Docetaxel as salvage therapy in highly pretreated and drug resistant gastrointestinal carcinomas. <i>Clinical Medicine Oncology</i> , <b>2008</b> , 2, 555-61		1
135	Treatment of CrohnB disease with leflunomide as second-line immunosuppression: a phase 1 open-label trial on efficacy, tolerability and safety. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 1025-32	4	15

134	Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , <b>2008</b> , 48, 169-76	11.2	1166
133	The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. <i>Journal of Clinical Investigation</i> , <b>2008</b> , 118, 2415-26	15.9	81
132	Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 3819-28	5.6	14
131	Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 3829-40	5.6	31
130	VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 4156-67	5.6	32
129	IL-28A is a key regulator of T-cell-mediated liver injury via the T-box transcription factor T-bet. <i>Gastroenterology</i> , <b>2007</b> , 132, 358-71	13.3	31
128	Chromoscopy-guided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. <i>Gastroenterology</i> , <b>2007</b> , 132, 874-82	13.3	454
127	Endoscopic surveillance in ulcerative colitis: smart biopsies do it better. <i>Gastroenterology</i> , <b>2007</b> , 133, 742-5	13.3	16
126	Interobserver Variation and Standardized Training for Confocal Laser Endomicroscopy Image Interpretation in the Upper and Lower GI Tract. <i>Gastrointestinal Endoscopy</i> , <b>2007</b> , 65, AB354	5.2	6
125	Methylene blue-aided cholangioscopy unravels the endoscopic features of ischemic-type biliary lesions after liver transplantation. <i>Gastrointestinal Endoscopy</i> , <b>2007</b> , 66, 1052-8	5.2	23
124	Exacerbation of ulcerative colitis after rituximab salvage therapy. <i>Inflammatory Bowel Diseases</i> , <b>2007</b> , 13, 1365-8	4.5	192
123	Lung CD11c+ cells from mice deficient in Epstein-Barr virus-induced gene 3 (EBI-3) prevent airway hyper-responsiveness in experimental asthma. <i>European Journal of Immunology</i> , <b>2007</b> , 37, 1663-77	6.1	11
122	IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. <i>European Journal of Immunology</i> , <b>2007</b> , 37, 1809-16	6.1	150
121	Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation. <i>Transplant International</i> , <b>2007</b> , 20, 583-90	3	36
120	Hepatitis viruses: live and let die. <i>Liver International</i> , <b>2007</b> , 27, 293-301	7.9	38
119	Enhanced sensitivity to CD95-induced apoptosis in ob/ob mice. <i>Digestive Diseases and Sciences</i> , <b>2007</b> , 52, 2396-402	4	12
118	Technology insight: confocal laser endoscopy for in vivo diagnosis of colorectal cancer. <i>Nature Clinical Practice Oncology</i> , <b>2007</b> , 4, 480-90		82
117	Regulation of B cell homeostasis and activation by the tumor suppressor gene CYLD. <i>Journal of Experimental Medicine</i> , <b>2007</b> , 204, 2615-27	16.6	79

116	The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer. <i>Gut</i> , <b>2007</b> , 56, 1572-8	19.2	38
115	Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. <i>International Immunology</i> , <b>2007</b> , 19, 685-93	4.9	47
114	Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. <i>Journal of Immunology</i> , <b>2007</b> , 179, 2041-5	5.3	183
113	Targeting of the transcription factor STAT4 by antisense phosphorothioate oligonucleotides suppresses collagen-induced arthritis. <i>Journal of Immunology</i> , <b>2007</b> , 178, 3427-36	5.3	50
112	Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. <i>Journal of Clinical Gastroenterology</i> , <b>2007</b> , 41, 103-10	3	64
111	Genome-wide analysis of factors regulating gene expression in liver. <i>Gene</i> , <b>2007</b> , 389, 114-21	3.8	6
110	In vivo subsurface morphological and functional cellular and subcellular imaging of the gastrointestinal tract with confocal mini-microscopy. <i>World Journal of Gastroenterology</i> , <b>2007</b> , 13, 2160	- <b>5</b> .6	26
109	Coexpression of receptor-tyrosine-kinases in gastric adenocarcinomaa rationale for a molecular targeting strategy?. <i>World Journal of Gastroenterology</i> , <b>2007</b> , 13, 3605-9	5.6	31
108	Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report. <i>BMC Cancer</i> , <b>2006</b> , 6, 190	4.8	24
107	Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. <i>BMC Cancer</i> , <b>2006</b> , 6, 232	4.8	80
106	Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma. <i>BMC Cancer</i> , <b>2006</b> , 6, 290	4.8	44
105	Hepatitis C virus re-infection: new perspectives. Clinical Transplantation, 2006, 20 Suppl 17, 117-23	3.8	1
104	Current bioinformatics tools in genomic biomedical research (Review). <i>International Journal of Molecular Medicine</i> , <b>2006</b> , 17, 967	4.4	5
103	Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. <i>Journal of Immunology</i> , <b>2006</b> , 176, 640-51	5.3	162
102	Cutting edge: IL-23 cross-regulates IL-12 production in T cell-dependent experimental colitis. Journal of Immunology, <b>2006</b> , 177, 2760-4	5.3	192
101	Pregnancy in autoimmune hepatitis: outcome and risk factors. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 556-60	0.7	164
100	Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. Journal of Experimental Medicine, <b>2006</b> , 203, 1875-81	16.6	143
99	Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , <b>2006</b> , 101, 2731-6	0.7	67

98	Nitric oxide promotes resistance to tumor suppression by CTLs. <i>Journal of Immunology</i> , <b>2006</b> , 176, 392	3- <u>3</u> .0	2
97	In vivo histology of Barrettß esophagus and associated neoplasia by confocal laser endomicroscopy. <i>Clinical Gastroenterology and Hepatology</i> , <b>2006</b> , 4, 979-87	6.9	416
96	Microscopic Changes in Non Erosive Reflux Disease (NERD) Can Be Diagnosed During Ongoing Endoscopy By Confocal Laser Endomicroscopy (CLE). <i>Gastrointestinal Endoscopy</i> , <b>2006</b> , 63, AB243	5.2	3
95	The role of apoptosis versus oncotic necrosis in liver injury: facts or faith?. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 984-93	13.4	28
94	Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. <i>Journal of Hepatology</i> , <b>2006</b> , 45, 419-28	13.4	186
93	Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients. World Journal of Gastroenterology, <b>2006</b> , 12, 5513-6	5.6	15
92	Das Interdisziplinde Hepatologische Zentrum Mainz. <i>Visceral Medicine</i> , <b>2006</b> , 22, 219-223	2.4	0
91	Actin binding LIM protein 3 (abLIM3). International Journal of Molecular Medicine, 2006, 17, 129	4.4	1
90	Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease. <i>Oncology Reports</i> , <b>2006</b> , 16, 1159	3.5	4
89	Overexpression of STAT-1 by adenoviral gene transfer does not inhibit hepatitis B virus replication. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2006</b> , 18, 167-74	2.2	2
88	Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma <b>2006</b> , 28, 25		10
87	Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers <b>2006</b> , 29, 973		6
86	Alloimmune hemolytic anemia after liver transplantation from an ABO-identical and Rh-nonidentical donor in a patient with postpartum Budd-Chiari syndrome. <i>Transplant International</i> , <b>2006</b> , 19, 514-5	3	2
85	Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy. <i>Liver International</i> , <b>2006</b> , 26, 319-25	7.9	25
84	Apoptosis in liver disease. <i>Liver International</i> , <b>2006</b> , 26, 904-11	7.9	87
83	Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. <i>Digestive Diseases and Sciences</i> , <b>2006</b> , 51, 1516-24	4	66
82	Crohnß-like colitis in a patient with immunodeficiency associated with a defect in expression of inducible costimulator. <i>Digestive Diseases and Sciences</i> , <b>2006</b> , 51, 711-7	4	9
81	Characterization of human gene encoding SLA/LP autoantigen and its conserved homologs in mouse, fish, fly, and worm. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 902-7	5.6	5

80	Characterization of OEBT, a LIM protein. International Journal of Molecular Medicine, 2005, 15, 513	4.4	
79	In silico characterization of an Iroquois family-related homeodomain protein. <i>International Journal of Molecular Medicine</i> , <b>2005</b> , 16, 443	4.4	
78	LASS6, an additional member of the longevity assurance gene family. <i>International Journal of Molecular Medicine</i> , <b>2005</b> , 16, 905	4.4	2
77	Colorectal cancer. Lancet, The, <b>2005</b> , 365, 153-65	40	863
76	6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohnß disease. <i>Clinical Gastroenterology and Hepatology</i> , <b>2005</b> , 3, 1007-14	6.9	76
75	Diagnosing Helicobacter pylori in vivo by confocal laser endoscopy. <i>Gastroenterology</i> , <b>2005</b> , 128, 2119-2	23:3.3	145
74	Hepatic over-expression of TGF-beta1 promotes LPS-induced inflammatory cytokine secretion by liver cells and endotoxemic shock. <i>Immunology Letters</i> , <b>2005</b> , 101, 217-22	4.1	25
73	Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. <i>American Journal of Gastroenterology</i> , <b>2005</b> , 100, 64-72	0.7	173
72	Reduced expression of Hugl-1, the human homologue of Drosophila tumour suppressor gene lgl, contributes to progression of colorectal cancer. <i>Oncogene</i> , <b>2005</b> , 24, 3100-9	9.2	117
71	MORT1/FADD is involved in liver regeneration. World Journal of Gastroenterology, 2005, 11, 7248-53	5.6	11
70	Asthmatic changes in mice lacking T-bet are mediated by IL-13. International Immunology, 2005, 17, 993	-140907	70
69	The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. <i>Cancer Research</i> , <b>2005</b> , 65, 10255-64	10.1	89
68	EBV-induced gene 3 transcription is induced by TLR signaling in primary dendritic cells via NF-kappa B activation. <i>Journal of Immunology</i> , <b>2005</b> , 174, 2814-24	5.3	127
67	Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells. <i>Cancer Research</i> , <b>2005</b> , 65, 10830-7	10.1	47
66			
	A genetic basis for IFN-gamma production and T-bet expression in humans. <i>Journal of Immunology</i> , <b>2005</b> , 175, 5457-62	5.3	29
65	- · · · · · · · · · · · · · · · · · · ·	5·3 4.6	<ul><li>29</li><li>79</li></ul>
6 <sub>5</sub>	2005, 175, 5457-62  Apoptosis and age-dependant induction of nuclear and mitochondrial etheno-DNA adducts in Long-Evans Cinnamon (LEC) rats: enhanced DNA damage by dietary curcumin upon copper		

# (2004-2004)

62	TGFbeta regulates the CD4+CD25+ T-cell pool and the expression of Foxp3 in vivo. <i>International Immunology</i> , <b>2004</b> , 16, 1241-9	4.9	84
61	(Neo)adjuvant strategies of advanced gastric carcinoma: time for a change?. <i>Digestive Diseases</i> , <b>2004</b> , 22, 345-50	3.2	14
60	Chromoendoscopy and magnifying endoscopy in patients with gastroesophageal reflux disease. Useful or negligible?. <i>Digestive Diseases</i> , <b>2004</b> , 22, 142-7	3.2	19
59	Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. <i>Journal of Immunology</i> , <b>2004</b> , 173, 6526-31	5.3	341
58	A critical regulatory role of leucin zipper transcription factor c-Maf in Th1-mediated experimental colitis. <i>Journal of Immunology</i> , <b>2004</b> , 173, 3446-55	5.3	10
57	Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. <i>Oncogene</i> , <b>2004</b> , 23, 3732-6	9.2	99
56	The human protein Hugl-1 substitutes for Drosophila lethal giant larvae tumour suppressor function in vivo. <i>Oncogene</i> , <b>2004</b> , 23, 8688-94	9.2	102
55	Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. <i>BMC Cancer</i> , <b>2004</b> , 4, 38	4.8	22
54	Current concept of pathophysiological understanding and natural course of ulcerative colitis. Langenbeckbs Archives of Surgery, <b>2004</b> , 389, 341-9	3.4	15
53	A stage-specific functional role of the leucine zipper transcription factor c-Maf in lung Th2 cell differentiation. <i>European Journal of Immunology</i> , <b>2004</b> , 34, 3401-12	6.1	11
52	HSP60 and CpG-DNA-oligonucleotides differentially regulate LPS-tolerance of hepatic Kupffer cells. <i>Immunology Letters</i> , <b>2004</b> , 93, 199-204	4.1	28
51	Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. <i>Journal of Immunology</i> , <b>2004</b> , 172, 5149-53	5.3	956
50	Placenta-derived CD95 ligand causes liver damage in hemolysis, elevated liver enzymes, and low platelet count syndrome. <i>Gastroenterology</i> , <b>2004</b> , 126, 849-58	13.3	44
49	Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. <i>Gastroenterology</i> , <b>2004</b> , 127, 706-13	13.3	695
48	Susceptibility to collagen-induced arthritis is modulated by TGFbeta responsiveness of T cells. <i>Arthritis Research</i> , <b>2004</b> , 6, R114-9		35
47	TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. <i>Immunity</i> , <b>2004</b> , 21, 491-501	32.3	608
46	Sensitizing to apoptosissharpening the medical sword. <i>Journal of Hepatology</i> , <b>2004</b> , 40, 335-6	13.4	23
45	Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure. <i>Journal of Hepatology</i> , <b>2004</b> , 41, 67-74	13.4	36

44	In vivo Fluorescence Confocal Laser Colonoscopy for Prediction of Neoplasia in Patients with Ulcerative Colitis. <i>Gastrointestinal Endoscopy</i> , <b>2004</b> , 59, P97	5.2	6
43	Safety and Efficacy of Methylene Blue-Aided Chromoendoscopy in Ulcerative Colitis: A Prospective Pilot Study Upon Previous Chromoendoscopies. <i>Gastrointestinal Endoscopy</i> , <b>2004</b> , 59, P97	5.2	8
42	Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. Journal of General Virology, <b>2004</b> , 85, 2829-2836	4.9	39
41	Treatment of patients with CrohnB disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF. <i>American Journal of Gastroenterology</i> , <b>2003</b> , 98, 504-5	0.7	34
40	Hepatic disseminated tumor cells in colorectal cancer UICC stage 4 patients: Prognostic implications <b>2003</b> , 23, 791		1
39	Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. <i>Chemotherapy</i> , <b>2003</b> , 49, 85-9	3.2	6
38	Impairment of TGF-beta signaling in T cells increases susceptibility to experimental autoimmune hepatitis in mice. <i>American Journal of Physiology - Renal Physiology</i> , <b>2003</b> , 284, G525-35	5.1	45
37	Dominant negative MORT1/FADD rescues mice from CD95 and TNF-induced liver failure. <i>Hepatology</i> , <b>2003</b> , 37, 129-35	11.2	21
36	A key pathogenic role for the STAT1/T-bet signaling pathway in T-cell-mediated liver inflammation. <i>Hepatology</i> , <b>2003</b> , 38, 1573-80	11.2	30
35	Retreatment with pegylated interferon-alpha2b plus ribavirin in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin. <i>Gastroenterology</i> , <b>2003</b> , 124, A768	13.3	4
34	Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. <i>Gastroenterology</i> , <b>2003</b> , 124, 880-8	13.3	735
33	Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. <i>Journal of Clinical Investigation</i> , <b>2003</b> , 112, 693-706	15.9	262
32	Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn® disease and promotes experimental colitis in vivo. <i>European Journal of Immunology</i> , <b>2002</b> , 32, 3142-51	6.1	67
31	Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. <i>Journal of Immunology</i> , <b>2002</b> , 169, 6141-8	5.3	143
30	Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA. <i>Journal of Immunology</i> , <b>2002</b> , 168, 411-20	5.3	115
29	A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+ CD4+ T cells: insights into the regulatory role of interleukin-6 on apoptosis. <i>Pathobiology</i> , <b>2002</b> , 70, 170-6	3.6	52
28	Dead or alive NF-kappaB, the guardian which tips the balance. <i>Journal of Hepatology</i> , <b>2002</b> , 36, 827-8	13.4	4
27	Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. <i>European Journal of Immunology</i> , <b>2001</b> , 31, 2071-9	6.1	43

### (2000-2001)

26	Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. <i>Journal of Experimental Medicine</i> , <b>2001</b> , 193, 1247-60	16.6	212
25	Effective infection, apoptotic cell killing and gene transfer of human hepatoma cells but not primary hepatocytes by parvovirus H1 and derived vectors. <i>Cancer Gene Therapy</i> , <b>2001</b> , 8, 158-67	5.4	63
24	Hepatocellular expression of a dominant-negative mutant TGF-beta type II receptor accelerates chemically induced hepatocarcinogenesis. <i>Oncogene</i> , <b>2001</b> , 20, 5015-24	9.2	63
23	Regulation of IL-12 p40 promoter activity in primary human monocytes: roles of NF-kappaB, CCAAT/enhancer-binding protein beta, and PU.1 and identification of a novel repressor element (GA-12) that responds to IL-4 and prostaglandin E(2). <i>Journal of Immunology</i> , <b>2001</b> , 167, 2608-18	5.3	78
22	Duration of immunosuppressive therapy in autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>2001</b> , 34, 354	<b>-5</b> 13.4	91
21	Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2001</b> , 107, 279-86	11.5	53
20	Regulation of T-cell apoptosis in inflammatory bowel disease: to die or not to die, that is the mucosal question. <i>Trends in Immunology</i> , <b>2001</b> , 22, 21-6	14.4	152
19	Immunotherapeutic approaches to inflammatory bowel diseases. <i>Expert Opinion on Biological Therapy</i> , <b>2001</b> , 1, 455-66	5.4	10
18	Apoptosis in liver disease. European Journal of Gastroenterology and Hepatology, 2001, 13, 785-90	2.2	53
17	Expression of stress protein gp96, a tumor rejection antigen, in human colorectal cancer. <i>International Journal of Cancer</i> , <b>2000</b> , 86, 489-93	7.5	21
16	Heterozygosity for the hemochromatosis gene in liver diseasesprevalence and effects on liver histology. <i>Liver International</i> , <b>2000</b> , 20, 482-6	7.9	27
15	Apoptosis and the liver. Seminars in Cancer Biology, <b>2000</b> , 10, 173-84	12.7	125
14	Reduced secretion of proinflammatory cytokines of monosodium urate crystal-stimulated monocytes in chronic renal failure: an explanation for infrequent gout episodes in chronic renal failure patients?. <i>Nephrology Dialysis Transplantation</i> , <b>2000</b> , 15, 644-9	4.3	28
13	Rapid development of Epstein-Barr virus-associated Hodgkinß disease after cessation of foscarnet therapy in an HIV-infected patient. <i>International Journal of STD and AIDS</i> , <b>2000</b> , 11, 609-10	1.4	3
12	IL-6 receptor independent stimulation of human gp130 by viral IL-6. <i>Journal of Immunology</i> , <b>2000</b> , 164, 4672-7	5.3	86
11	FDG-PET: A novel non-invasive method to detect affected bowel segments in Crohnß disease?. <i>Gastroenterology</i> , <b>2000</b> , 118, A320	13.3	2
10	Blockade of IL-6 transsignaling abrogates established experimental colitis in mice by suppression of T cell resistance against apoptosis. <i>Gastroenterology</i> , <b>2000</b> , 118, A863	13.3	3
9	Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration. <i>Gastroenterology</i> , <b>2000</b> , 119, 1663-71	13.3	100

8	A novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct is associated with increased TNF-alpha production and autoantibodies. <i>Journal of Hepatology</i> , <b>2000</b> , 33, 862-72	13.4	31
7	Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. <i>Journal of Hepatology</i> , <b>1999</b> , 31, 635-40	13.4	115
6	p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. <i>Journal of Experimental Medicine</i> , <b>1998</b> , 188, 2033-45	16.6	704
5	CD95-induced apoptosis in human liver disease. <i>Seminars in Liver Disease</i> , <b>1998</b> , 18, 141-51	7.3	101
4	Apoptosis in liver disease. <i>Journal of Hepatology</i> , <b>1997</b> , 27, 405-12	13.4	90
3	Serum antibodies against Helicobacter pylori proteins VacA and CagA are associated with increased risk for gastric adenocarcinoma. <i>Digestive Diseases and Sciences</i> , <b>1997</b> , 42, 1652-9	4	98
2	In vitro experimental infection of primary human hepatocytes with hepatitis B virus. <i>Gastroenterology</i> , <b>1994</b> , 106, 664-73	13.3	110
1	Chemokine receptor CCR7 enhances intrahepatic and lymphatic dissemination of human hepatocellular cancer. <i>Oncology Reports</i> ,	3.5	7